NEW YORK (GenomeWeb) – Molecular Stethoscope announced today the completion of an $8.2 million seed financing, which will enable the company to continue developing its liquid biopsy tests for cardiometabolic and neurodegenerative diseases.

Additionally, the company has signed a two-year research collaboration agreement with Pfizer to develop a blood-based assay that can identify subjects at critical stages of disease progression in key cardiometabolic conditions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.